Quick Read Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Quick Read FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Nvidia and Eli Lilly's AI tie-up shows drug discovery emerging as a new ETF growth theme across semiconductors and health care.

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million. The move marked a full exit from the position, which was previously ...